<DOC>
	<DOCNO>NCT02803307</DOCNO>
	<brief_summary>This trial multi-site , randomize , open-label , parallel , single-dose administration study investigate safety efficacy TLC599 subject osteoarthritis knee .</brief_summary>
	<brief_title>Single-Dose Administration Trial TLC599 Osteoarthritis Knee</brief_title>
	<detailed_description>Protocol No : TLC599A1001 Name Finished Product : TLC599 Title Study : A Randomized , Open-label , Parallel , Phase I/II Single-Dose Administration trial TLC599 Subjects Osteoarthritis ( OA ) Knee Methodology This trial multi-site , randomize , open-label , parallel , single-dose administration study investigate safety efficacy TLC599 subject osteoarthritis knee . Study duration : The trial last 14 week include 14-day screening period 12-week follow-up period .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>1 . Male female subject , least 20 year age 2 . Documented diagnosis OA knee least 6 month 3 . At least grade 2 severity base Kellgren Lawrence Grading Scale 4 . VAS score ≥ 4 baseline 1 . Subjects receive systemic corticosteroid last 30 day prior baseline 2 . Subjects receive nonsteroidal antiinflammatory drug ( NSAID ) , analgesic , rehabilitation therapy within 7 day prior baseline 3 . History rheumatoid arthritis autoimmune disease 4 . Clinical sign symptom acute infection infection relate inflammation knee dose 5 . History infective arthritis , suspect concurrent infection , suspect confirmed crystal disease ( gout pseudogout ) study knee 6 . Concurrent systemic active uncontrolled infectious disease 7 . A history treat malignancy disease free ≤ 5 year . ( The malignancy include nonbasalcell carcinoma skin carcinomainsitu uterine cervix ) 8 . History acquire congenital immunodeficiency diseases 9 . Platelet count &lt; 80,000/μl , blood coagulation disorder , include subject hemophilia , decompensated liver cirrhosis uremia 10 . Stroke myocardial infarction within 3 month prior screen visit 11 . Use intraarticular corticosteroid , hyaluronic acid , intraarticular injection study knee joint within 3 month prior screen visit 12 . Unstable study knee joint , include anterior cruciate ligament , surgery study knee within 12 month prior screen visit , prior arthroscopic open surgery study knee planned/anticipated surgery study period 13 . Any skin lesion/breakdown anticipate injection site condition impair penetration study knee joint space 14 . Female subject pregnant , nursing , plan pregnancy , childbearing potential use reliable mean contraception 15.Known allergy hypersensitivity study drug component</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoarthritis knee</keyword>
	<keyword>TLC599</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>DSP</keyword>
</DOC>